The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Flagged first, then by citations
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 101–200 of 1,000
Dörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1942 · Cited by 305
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
Fleischmann, R. M., Tesser, J., Schiff, M. H., Schechtman, J., Burmester, G.-R., Bennett, R., Modafferi, D., Zhou, L., Bell, D., & Appleton, B. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.048371 · Cited by 305
Hinks, A., Barton, A. C., John, S., Bruce, I. N., Hawkins, C., Griffiths, C. E. M., Donn, R. P., Thomson, W., Silman, A. J., & Worthington, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21049 · Cited by 304
State-of-the-art: rheumatoid arthritis
McInnes, I. B., & O’Dell, J. R. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134684 · Cited by 303
B-cell tolerance checkpoints in health and autoimmunity
Meffre, E., & Wardemann, H. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.09.001 · Cited by 304
Séror, R., Sordet, C., Guillevin, L., HACHULLA, E., Masson, C., Ittah, M., Candon, S., Guern, V. L., Aouba, A., Sibilia, J., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057919 · Cited by 301
Lafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novák, J., Nath, K. A., Sethi, S. M., Tumlin, J. A., Mehta, K. R., Hogan, M. C., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060640 · Cited by 301
Donahue, K. E., Gartlehner, G., Jonas, D. E., Lux, L. J., Thieda, P., Jonas, B., Hansen, R. A., Morgan, L. C., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00192 · Cited by 299
Gerlag, D. M., Safy‐Khan, M., Maijer, K. I., Tang, M. W., Tas, S. W., Kool, M. J. F., van Tubergen, A. M., Janssen, M., de Hair, M. J. H., Hansson, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212763 · Cited by 300
Roberts, D. M., Jones, R. B., Smith, R., Alberici, F., Kumararatne, D. S., Burns, S., & Jayne, D. R. W. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.11.009 · Cited by 299
The role of B cells in atherosclerosis
Sage, A. P., Tsiantoulas, D., Binder, C. J., & Mallat, Z. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0106-9 · Cited by 298
Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy
Lopez-Olivo, M. A., Tayar, J. H., Martínez-López, J. A., Pollono, E. N., Cueto, J. P., Gonzales-Crespo, M. R., Fulton, S., & Suarez-Almazor, M. E. (2012) · JAMA · doi:10.1001/2012.jama.10857 · Cited by 295
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Pellkofer, H., Krumbholz, M., Berthele, A., Hemmer, B., Gerdes, L. A., Havla, J. B., Bittner, R., Canis, M., Meinl, E., Hohlfeld, R., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182152881 · Cited by 296
Naredo, E., Rodríguez, M. V., Campos, C., Heredia, J. M. R., Medina, J. A., Giner, E., Martínez, O., Toyos, F. J., Ruíz, T., Ros, I., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23529 · Cited by 293
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
Fürst, D. E. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.10.002 · Cited by 291
Memory B and memory plasma cells
Yoshida, T., Mei, H. E., Dörner, T., Hiepe, F., Radbruch, A., Fillatreau, S., & Hoyer, B. F. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00938.x · Cited by 301
Cartin‐Ceba, R., Golbin, J. M., Keogh, K. A., Peikert, T., Sánchez-Menéndez, M. M., Ytterberg, S. R., Fervenza, F. C., & Specks, U. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34584 · Cited by 290
Menard, L. C., Saadoun, D., Isnardi, I., Ng, Y.-S., Meyers, G., Massad, C., Price, C. C., Abraham, C., Motaghedi, R., Buckner, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45790 · Cited by 289
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
van Vollenhoven, R., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R., Furst, D. E., Macey, K., Sweetser, M. T., Kelman, A., & Rao, R. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090856 · Cited by 288
Self-citationTargeting signal transduction as a strategy to treat inflammatory diseases
O'Neill, L. A. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2070 · Cited by 285
Campbell, L., Chen, C., Bhagat, S., Parker, R., & Östör, A. (2011) · Rheumatology · doi:10.1093/rheumatology/keq343 · Cited by 280
Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy
Alam, J., Jantan, I., & Bukhari, S. N. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.055 · Cited by 286
B cells expressing the transcription factor T-bet drive lupus-like autoimmunity
Rubtsova, K., Rubtsov, A. V., Thurman, J. M., Mennona, J. M., Kappler, J. W., & Marrack, P. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91250 · Cited by 274
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Browning, J. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2085 · Cited by 281
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 281
Cambridge, G., Stohl, W., Leandro, M. J., Migone, T., Hilbert, D. M., & Edwards, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21650 · Cited by 274
Self-citationExacerbation of ulcerative colitis after rituximab salvage therapy
Goetz, M., Atreya, R. N., Ghalibafian, M., Galle, P. R., & Neurath, M. F. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20215 · Cited by 268
Scully, M., Cohen, H., Cavenagh, J. D., Benjamin, S., Starke, R. D., Killick, S. B., Mackie, I. J., & Machin, S. J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06448.x · Cited by 267
Synovial tissue research: a state-of-the-art review
Orr, C. K., Vieira‐Sousa, E., Boyle, D. L., Buch, M. H., Buckley, C. D., Cañete, J. D. D., Catrina, A. I., Choy, E., Emery, P., Fearon, U., et al. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.115 · Cited by 266
Self-citationRituximab treatment of idiopathic membranous nephropathy
Fervenza, F. C., Cosío, B. G., Erickson, S. B., Specks, U., Herzenberg, A. M., Dillon, J. J., Leung, N., Cohen, I. M., Wochos, D. N., Bergstralh, E. J., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002628 · Cited by 264
Zaja, F. F., Baccarani, M., Mazza, P., Bocchia, M., Gugliotta, L., Zaccaria, A., Vianelli, N., Defina, M., Tieghi, A., Amadori, S., et al. (2010) · Blood · doi:10.1182/blood-2009-07-229815 · Cited by 262
Salvi, M., Vannucchi, G. M., Campi, I., Currò, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., et al. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02325 · Cited by 261
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 266
Cho, J. H., & Feldman, M. A. (2015) · Nature Medicine · doi:10.1038/nm.3897 · Cited by 267
Differences in innate immune response between man and mouse
Zschaler, J., Schlorke, D., & Arnhold, J. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014011600 · Cited by 264
Weitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 264
Rituximab in severe, treatment-refractory interstitial lung disease
Keir, G. J., Maher, T. M., Ming, D., Abdullah, R., de Lauretis, A., Wickremasinghe, M., Nicholson, A. G., Hansell, D. M., Wells, A. U., & Renzoni, E. A. (2014) · Respirology · doi:10.1111/resp.12214 · Cited by 256
Steinfeld, S. D., Tant, L., Burmester, G. R., Teoh, N., Wegener, W. A., Goldenberg, D. M., & Pradier, O. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2018 · Cited by 255
High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease
Sarantopoulos, S., Stevenson, K. E., Kim, H. T., Bhuiya, N. S., Cutler, C. S., Soiffer, R. J., Antin, J. H., & Ritz, J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1290 · Cited by 255
Anti-CD20 (rituximab) treatment improves atopic eczema
Simon, D., Radonjic‐Hoesli, S., Kostylina, G., Yawalkar, N., & Simon, H. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.016 · Cited by 253
Rituximab-Associated Infections
Gea‐Banacloche, J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.002 · Cited by 253
Conway, R. P., Low, C., Coughlan, R. J., O'Donnell, M. J., & CAREY, J. J. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38322 · Cited by 250
Vo, A. A., Peng, A., Toyoda, M., Kahwaji, J. M., Cao, K., Lai, C., Reinsmoen, N. L., Villicana, R., & Jordan, S. C. (2010) · Transplantation · doi:10.1097/tp.0b013e3181d21e7f · Cited by 248
Godeau, B., Porcher, R., Fain, O., Lefrère, F., Fenaux, P., Chèze, S., Vekhoff, A., Chauveheid, M., Stirnemann, J., Galicier, L., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131029 · Cited by 245
Oren, S., Mandelboim, M., Braun‐Moscovici, Y., Paran, D., Ablin, J. N., Litinsky, I., Comaneshter, D. S., Levartovsky, D., Mendelson, E., Azar, R., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.077461 · Cited by 242
Physiological and pathophysiological bone turnover — role of the immune system
Weitzmann, M. N., & Ofotokun, I. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.91 · Cited by 247
Gunnarsson, I., Sundelin, B., Jonsdottir, T., Jacobson, S. H., Henriksson, E. W., & van Vollenhoven, R. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22505 · Cited by 241
Mietzner, B., Tsuiji, M., Scheid, J. F., Velinzon, K., Tiller, T., Abraham, K., González, J., Pascual, V., Stichweh, D., Wardemann, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803644105 · Cited by 241
Dessein, P. H., Joffe, B. I., & Singh, S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1717 · Cited by 240
Vallerskog, T., Gunnarsson, I., Widhe, M., Risselada, A. P., Klareskog, L., van Vollenhoven, R., Malmström, V., & Trollmo, C. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.08.016 · Cited by 240
Gartlehner, G., Hansen, R. A., Jonas, B., Thieda, P., & Lohr, K. N. (2006) · PubMed · Cited by 239
Valiyil, R., Casciola-Rosen, L. A., Hong, G., Mammen, A. L., & Christopher‐Stine, L. (2010) · Arthritis Care & Research · doi:10.1002/acr.20219 · Cited by 236
The Effect of Inflammation on Bone
Epsley, S., Tadros, S., Farid, A., Kargilis, D., Mehta, S., & Rajapakse, C. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.511799 · Cited by 252
B‐cell targeted therapies in human autoimmune diseases: an updated perspective
Townsend, M. J., Monroe, J. G., & Chan, A. C. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00945.x · Cited by 240
Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.34329 · Cited by 236
Eriksson, P. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01494.x · Cited by 231
Cambridge, G., Leandro, M. J., Teodorescu, M., Manson, J. J., Rahman, A., Isenberg, D. A., & Edwards, J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22211 · Cited by 230
Self-citationAdaptive immunity in atherosclerosis: mechanisms and future therapeutic targets
Lahoute, C., Herbin, O., Mallat, Z., & Tedgui, A. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.62 · Cited by 235
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., Ghogomu, E. T., & Tugwell, P. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.091391 · Cited by 229
Keystone, E. C., Emery, P., PETERFY, C. G., Tak, P. P., Cohen, S. B., Genovese, M. C., Dougados, M., Burmester, G. R., Greenwald, M., Kvien, T. K., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.085787 · Cited by 228
Self-citationDavatchi, F., Shams, H., REZAIPOOR, M., Abdollahi, B. S., Shahram, F., Nadji, A., Chams‐Davatchi, C., Akhlaghi, M., Faezi, T., & NADERI, N. (2010) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2010.01546.x · Cited by 229
Consensus statement on the use of rituximab in patients with rheumatoid arthritis
Smolen, J. S., Keystone, E. C., Emery, P., Breedveld, F. C., Betteridge, N., Burmester, G. R., Dougados, M., Ferraccioli, G., Jaeger, U., Klareskog, L., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.061002 · Cited by 228
Self-citationNew learnings on the pathophysiology of RA from synovial biopsies
Pitzalis, C., Kelly, S., & Humby, F. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835fd8eb · Cited by 224
Pathogenic Roles of B Cells in Human Autoimmunity
Martin, F., & Chan, A. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00112-8 · Cited by 223
Does rituximab increase the incidence of infectious complications? A narrative review
Kelesidis, T., Daikos, G. L., Boumpas, D. T., & Tsiodras, S. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.03.025 · Cited by 222
Chatzidionysiou, K., Lie, E., Nasonov, E. L., Lukina, G. V., Hetland, M. L., Tarp, U., Gabay, C., van Riel, P. L. C. M., Nordström, D., Gómez-Reino, J. J., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.148759 · Cited by 222
Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
Paniagua, R. T., Sharpe, O., Ho, P. P.-K., Chan, S. M., Chang, A., Higgins, J. P., Tomooka, B. H., Thomas, F. M., Song, J. J., Goodman, S. B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28546 · Cited by 214
Biologic therapies in rheumatology: lessons learned, future directions
Strand, V., Kimberly, R. P., & Isaacs, J. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2196 · Cited by 223
Stasi, R., Stipa, E., Poeta, G. D., Amadori, S., Newland, A. C., & Provan, D. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel098 · Cited by 218
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
Naismith, R. T., Piccio, L. M., Lyons, J., Lauber, J., Tutlam, N. T., Parks, B. J., Trinkaus, K. M., Song, S. K., & Cross, A. H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24373 · Cited by 217
Tocilizumab: The first interleukin-6-receptor inhibitor
Sebba, A. I. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070449 · Cited by 219
Tony, H., Burmester, G. R., Schulze‐Koops, H., Grünke, M., Henes, J. C., Kötter, I., Haas, J., Unger, L., Lovric, S., Haubitz, M., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3337 · Cited by 213
Franquesa, M., Mensah, F. K., Huizinga, R., Strini, T., Boon, L., Lombardo, E., DelaRosa, O., Laman, J. D., Grinyo, J. M., Weimar, W., et al. (2014) · Stem Cells · doi:10.1002/stem.1881 · Cited by 213
Ohata, J., Zvaifler, N. J., Nishio, M., Boyle, D. L., Kalled, S. L., Carson, D. A., & Kipps, T. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.864 · Cited by 212
Crawford, D. C., DeBerardino, T. M., & Williams, R. J. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00533 · Cited by 211
Pine, P. R., Chang, B. Y., Schoettler, N., Banquerigo, M. L., Wang, S., Lau, A., Zhao, F., Grossbard, E. B., Payan, D. G., & Brahn, E. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.03.543 · Cited by 209
Albert, D., Dunham, J., Khan, S., Stansberry, J., Kolasinski, S. L., Tsai, D., Pullman‐Mooar, S., Barnack, F., Striebich, C. C., Looney, R. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083162 · Cited by 209
A Pilot Trial of Rituximab in the Treatment of Patients With Dermatomyositis
Chung, L. S., Genovese, M. C., & Fiorentino, D. F. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.763 · Cited by 209
Genovese, M. C., Kaine, J., Lowenstein, M. B., Giudice, J. D., Baldassare, A. R., Schechtman, J., Fudman, E. J., Kohen, M. D., Gujrathi, S., Trapp, R. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23732 · Cited by 208
Tak, P. P., Thurlings, R. M., Rossier, C., Nestorov, I. A., Dimic, A., Mircetić, V., Rischmueller, M., Nasonov, E. L., Шмидт, Е., Emery, P., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23178 · Cited by 207
Self-citationMikulska, M., Lanini, S., Gudiol, C., Drgoňa, Ľ., Ippolito, G., Fernández‐Ruiz, M., & Salzberger, B. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.003 · Cited by 215
Ravani, P., Magnasco, A., Edefonti, A., Murer, L., Rossi, R., Ghio, L., Benetti, E., Scozzola, F., Pasini, A., Dallera, N., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09421010 · Cited by 206
Vogel, W. H. (2010) · Clinical journal of oncology nursing · doi:10.1188/10.cjon.e10-e21 · Cited by 213
Rituximab in the treatment of autoimmune haematological disorders
Garvey, B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07054.x · Cited by 204
Ng, C. M., Bruno, R., Combs, D., & Davies, B. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005277075 · Cited by 203
Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody
Stangl, S., Gehrmann, M., Riegger, J., Kuhs, K., Riederer, I., Sievert, W., Hube, K., Mocikat, R., Dressel, R., Kremmer, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016065108 · Cited by 202
Sfikakis, P. P., Souliotis, V. L., Fragiadaki, K., Moutsopoulos, H. Μ., Boletis, J., & Theofilopoulos, A. N. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.12.006 · Cited by 203
Song, I. ‐., Heldmann, F., Rudwaleit, M., Listing, J., Appel, H., Braun, J., & Sieper, J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27383 · Cited by 200
Lavie, F., Miceli‐Richard, C., Ittah, M., Sellam, J., Gottenberg, J., & Xavier Mariette, A. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.060772 · Cited by 199
Monach, P. A., Mathis, D. J., & Benoist, C. O. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1522s81 · Cited by 197
Regulatory B cells in autoimmune diseases
Yang, M., Rui, K., Wang, S., & Lu, L. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.60 · Cited by 202
Roger S. Mitchell Lecture. Rheumatoid Lung Disease
Brown, K. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200703-045ms · Cited by 196
Animal models of chronic pain: Advances and challenges for clinical translation
Burma, N. E., Leduc‐Pessah, H., Fan, C. Y., & Trang, T. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23768 · Cited by 198
Kasi, P. M., Tawbi, H. A.-H., Oddis, C. V., & Kulkarni, H. S. (2012) · Critical Care · doi:10.1186/cc11304 · Cited by 196
Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
Vos, K., Thurlings, R. M., Wijbrandts, C. A., van Schaardenburg, D., Gerlag, D. M., & Tak, P. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22400 · Cited by 194
Regulation of Immune Responses and Chronic Inflammation by Fibroblast-Like Synoviocytes
Yoshitomi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01395 · Cited by 197
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Nazi, I., Kelton, J. G., Larché, M., Snider, D. P., Heddle, N. M., Crowther, M. A., Cook, R. J., Tinmouth, A. T., Mangel, J. E., & Arnold, D. M. (2013) · Blood · doi:10.1182/blood-2013-04-494096 · Cited by 192
Biologic therapies and bone loss in rheumatoid arthritis
Zerbini, C., Clark, P., Méndez-Sánchez, L., Pereira, R. M., Messina, O. D., Uña, C., Adachi, J., Lems, W., Cooper, C., & Lane, N. (2017) · Osteoporosis International · doi:10.1007/s00198-016-3769-2 · Cited by 185
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes
Shamsili, S., de Beukelaar, J., Gratama, J. W., Hooijkaas, H., van den Bent, M. J., Veer, M. B. V., & Smitt, P. A. E. S. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0882-0 · Cited by 191
Systemic Rheumatoid Vasculitis: A Review
Genta, M. S., Genta, R. M., & Gabay, C. (2006) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.04.006 · Cited by 190
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
